NAME OF THE ISSUE: KRONOX LAB SCIENCES LIMITED

1	Type of issue (IPO/ FPO) : Initial Public Offer (IPO) on Mainboard Platform								
1	Type of issue (IPO/ FPO)	•	Initial Public Offer (IPO) on Mainboard Platform						
2	Issue size (Rs Crore)	:	130.15						
3	Grade of issue along with name of the rating agency	:	NA						
4	Subscription level (number of times). If the issue was								
	undersubscribed, please clarify how the funds were	:	32.61 times (after technical rejection)						
	arranged.								
5	QIB holding (as a % of total outstanding capital) as								
	disclosed to stock exchanges (See Regulation 31 of the								
	SEBI Listing Obligations & Disclosure Requirements),								
	2015)								
	(i) allotment in the issue	:	12.89%						
	(ii) at the end of the 1 st Quarter immediately after the		C 00%						
	listing of the issue	:	6.99%						
	(iii) at the end of 1 st FY (March 31, 2025)	•••	Will be updated						
	(iv) at the end of 2 nd FY (March 31, 2026)	:	Will be updated						
	(v) at the end of 3^{rd} FY (March 31, 2027)	:	Will be updated						
	Financials of the insurant for your the annual financial								
6	Financials of the issuer (as per the annual financial		Deveryone to use			Rs. in Crores)			
	results submitted to stock exchanges under Regulation		Parameters	1 st FY	2 nd FY	3 rd FY			
	33 of the SEBI Listing Obligations & Disclosure			(March 31,	(March 31,	(March 31,			
	Requirements) , 2015)	:		2025)	2026)	2027)			
			Income From Operations						
			Net Profit for the Period	Will be	Will be	Will be			
			Paid-up equity share capital	Updated	Updated	Updated			
			Reserves excluding revaluation reserves						
7	Trading status in the scrip of the issuer (whether								
	frequently traded (as defined under Regulation 2 (j) of								
	SEBI (SAST) Regulations, 2011) or infrequently traded /	•							
	delisted / suspended by any stock exchange, etc.)								

	(i) at the end of 1 st FY (March 31, 2025)	:	Will be updated
	(ii) at the end of 2 nd FY (March 31, 2026)	:	Will be updated
	(iii) at the end of 3 rd FY (March 31, 2027)	:	Will be updated
8	Change, if any, in directors of issuer from the disclosures		
	in the offer document (See Regulation 30 of the SEBI		
	(Listing Obligations & Disclosure Requirements), 2015)		
	(i) at the end of 1 st FY (March 31, 2025)	:	Will be updated
	(ii) at the end of 2 nd FY (March 31, 2026)	:	Will be updated
	(iii) at the end of 3 rd FY (March 31, 2027)	:	Will be updated
9	Status of implementation of project / common compart of		ΝΑ
9	Status of implementation of project/ commencement of commercial production (as submitted to stock		
	exchanges under Regulation 32 of the SEBI (Listing		
	Obligations & Disclosure Requirements) , 2015)		
	(i) as disclosed in the offer document		
	(ii) Actual implementation	:	
	(iii) Reasons for delay in implementation , if any	:	
		•	
10	Status of utilization of issue proceeds (as submitted to		
	stock exchanges under (as submitted to stock exchanges		
	under Regulation 32 of the SEBI (Listing Obligations &		NA
	Disclosure Requirements) , 2015)		
	(i) as disclosed in the offer document		
		:	
	(ii) Actual utilization	:	
	(iii) Reasons for deviation, if any	:	
11	Comments of monitoring agency, if applicable (See		NA
	Regulation 41& 137 of SEBI (ICDR) Regulations, 2018		
	read with Regulation 32 of the SEBI Listing Obligations &		
	Disclosure Requirements) , 2015))		
	(a) Comments on use of funds		

	(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document		
	(c) Any other reservation expressed by the monitoring agency about the use of funds		
12	Price- related data		
12	Issue price (Rs):	:	Rs.136/-

Price	At close of listing day	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day	As at the end of 1 st FY after the listing of the issue (March 31, 2025)			As at the end of 2nd FY after the listing of the issue (March 31, 2026)			As at the end of 3rd FY after the listing of the issue(March 31, 2027)		
parameters				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price	159.35 ¹	158.99	172.23	NA	NA	NA	NA	NA	NA	NA	NA	NA
Index (of the Designated Stock Exchange): NSE Nifty 50	23,259.20	24,433.20	24852.15	NA	NA	NA	NA	NA	NA	NA	NA	NA
Sectorial Index (mention the index that has been considered and reasons for considering the same): NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

¹ Due to non-availability of share price data of the Company for June 10, 2024 (i.e. date of listing) on NSE website, market price data available on BSE website is mentioned above

13 Basis for Issue Price and Comparison with Peer Group & Industry Average (Source of accounting ratios of peer group and industry average may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated):

Accounting ratio	Name of company	As disclosed in the offer document	At the end of 1 st FY (March 31, 2025)	At the end of 2 nd FY (March 31, 2026)	At the end of 3 rd FY (March 31, 2027)
	Issuer (Basic and Diluted)	4.30			
	Peer Group:-				Will be updated
	Tatva Chintan Pharma Chem Limited	19.45			
EPS	Tanfac Industries Limited	56.27	-		
2.0	Neogen Chemicals Limited	18.94	-	Will be updated	
	Sigachi Industries Limited	1.42	Will be updated		
	DMCC Speciality Chemical Limited	2.78			
	Industry Avg	19.77			
	Issuer	31.63			
	Industry Avg.	67.5 ²			
	Peer Group:				
D / F	Tatva Chintan Pharma Chem				
P/E	Limited	57.57			
	Tanfac Industries Limited	39.15			
	Neogen Chemicals Limited	77.55			
	Sigachi Industries Limited	46.64			
	DMCC Speciality Chemical Limited	116.57			
	Issuer	37.19%			
	Peer Group (Global):-		-		
	Tatva Chintan Pharma Chem				
RoNW	Limited	8.84%			
	Tanfac Industries Limited	30.46%			
	Neogen Chemicals Limited	10.36%			
	Sigachi Industries Limited	16.22%			

² Source Prospectus.

Accounting ratio	Name of company	As disclosed in the offer document	At the end of 1 st FY (March 31, 2025)	At the end of 2 nd FY (March 31, 2026)	At the end of 3 rd FY (March 31, 2027)
	DMCC Speciality Chemical Limited	3.50%			
	Industry Avg.	13.87%			
	Issuer:	12.04			
	Peer Group (Global):				
	Tatva Chintan Pharma Chem				
NAV per	Limited	220.07			
share based on balance	Tanfac Industries Limited	184.74			
sheet	Neogen Chemicals Limited	182.90			
Sileet	Sigachi Industries Limited	8.73			
	DMCC Speciality Chemical Limited	79.49			
	Industry Avg	135.18			

14 Any other material information: NA

Notes:

1. Shares of the Company were listed on June 10, 2024 therefore March 31, 2025 shall be 1st Financial Year after listing.

2. QIBs include Anchor Investor and excludes Pre Issue holdings if any. Calculated as a % of post issue outstanding shares.